The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/metastatic solid tumours with homologous recombination repair (HRR) deficiencies.
Documented locally advanced or metastatic solid tumour malignancy.
Eastern cooperative oncology group (ECOG) performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to screening and first day of dosing.
Minimum life expectancy ≥ 12 weeks.
Adequate organ and marrow function.
Any significant laboratory finding or any severe and uncontrolled medical condition.
Participants with any known predisposition to bleeding.
Spinal cord compression or symptomatic and unstable brain metastases or leptomeningeal disease.
Allogenic organ transplantation.
6
Treatment groupsSee each treatment group below.